upsid top-lin guid steal show
solid print albeit move piec
report solid result morn see first look although margin
came light favor tax help drive ep beat number minor
surpris print robust growth ou particularli companion anim
attribut new product increment launch ie rimadyl china
elev sg spend even elev target due increment field forc
incent payment bonu true-up given strong perform overal
howev quarter larg expect wrap strong year
question besid trio conserv guid
go print expect initi guid core sale
growth adj ep vein posit surpris
core sale target although note includ almost contribut
assum organ target roughli in-lin yet ep target
even lower anticip main take-away management feel
broadli posit end-market particularli livestock expect
growth everi speci bolster global rebound off-set loss china
pig herd due asf earn growth somewhat hamper gross margin
line fx turn tailwind wors headwind
addit spend sg support upcom trio launch futur
product biggest near-term catalyst stock trio approv
us still expect late contribut although management reveal
us launch wont week approv debat much
conservat built outlook given prior histori hearti beat-and-rais
estim larg unchang reiter neutral
overal revenu estim mostli unchang adj ep trim modestli
look forward detail review guid move piec
upcom anim health summit feb maintain neutral rate rais
po ep estimate due higher organ growth
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
zoeti global leader discoveri
develop manufactur
commerci anim health medicin
vaccin product companion
anim market well-diversifi portfolio
product line span eight core
speci five therapeut categori directli
market countri industri
believ zoeti benefit rise
demand companion product anim
health product particularli emerg market
new product product line extens
expand ancillari servic offer greater
oper work capit effici
opportunist invest acquisit and/or
partnership supplement growth howev
see valuat full given expect
alreadi high see limit room
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
po base ep estim back dcf
assum wacc termin growth rate roughli in-lin
current multipl albeit slightli higher recent valuat trend
believ justifi given upsid new product launch increment capit
deploy margin expans opportun defens natur
upsid risk continu ramp new product larger-than-expect contribut
futur launch acceler growth abaxi acquisit
downsid risk price object competit select market new product
launch competitor weaker demand anim health product regulatori issu
failur get approv key product pipelin macroeconom
condit currenc risk headwind relat regul antibiot use
michael ryskin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
